The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
- Your 7 Decisions To Make Before MES Configuration
GUEST COLUMNISTS
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
-
Is Your Supply Chain Ready For The End Of Class VI?
Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.
-
When Lyophilization Fails At Scale, First Scrutinize Your Formulation
When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
Your 7 Decisions To Make Before MES Configuration
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
BIOSIMILAR WHITE PAPERS
-
Process Analytical Technology In The ADC Bioconjugation Process
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Process Intensification And Other Ways To Adapt To Changing Needs7/20/2026
As biologics manufacturing evolves, gain insight into why productivity depends on smarter investments, flexible production strategies, and supplier support that can address shifting modalities.
-
Aseptic Process Design And Simulation Under Annex 1 Guidelines1/9/2026
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Fresenius And WuXi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline
- AAM Comments On Department Of Labor PBM Transparency And Disclosure Rule
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Adalvo Expands Biosimilars Portfolio Through Acquisition Of Romiplostim Biosimilar Programme From Enzene
- FDA Approves Lucamzi – Biosimilar To Lucentis
- BioSim Proposes Incorporating Measures Into Electoral Programs To Promote Biosimilar Medicines
- Bio-Thera Announces NMPA Approval Of BAT2306, The First Secukinumab Biosimilar Approved In China
- Samsung Bioepis Releases Fourth Quarter 2026 Biosimilar Market Report Highlighting Importance Of Supply Continuity
NEWSLETTER ARCHIVE
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
- 10.22.26 -- FDA Modernizes Container Closure Guidance: What Is Changing
- 10.21.26 -- A Sustainable Future: Leveraging 3Rs To Innovate And Accelerate In Testing
